Exystat
Exystat is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)
Sponsor Imcheck Therapeutics
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 44 participants at five centers in France, Germany, and the United Kingdom.
- Protocol amendments modified inclusion criteria and added or clarified exclusion criteria.
- Protocol amendments increased the Part 1 sample size, added and omitted dose-escalation cohorts, and added pembrolizumab as study treatment.
These findings describe the trial, not the service provider’s performance or responsibility.
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI) - ARTEMIA study
Sponsor OSE Immunotherapeutics
- Start (EU)
- Latest update
- Estimated end
A multicenter phase 1/2 dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas
Sponsor OSE Immunotherapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3
Sponsor Biocodex
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Etifoxine Monotherapy in The Treatment of Adjustment Disorder with Anxiety (ADWA)
Sponsor Biocodex
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and safety of the elranatamab-lenalidomide combination as a replacement for chemotherapy followed by autologous stem cell transplant in the consolidation phase, and to compare elranatamab with standard of care in the maintenance phase (ElLen; IFM 2025-01)
Sponsor Intergroupe Francophone Du Myelome
- Start (EU)
- Latest update
- Estimated end
- Not reported
A double-blind, randomized, placebo-controlled, multicenter trial evaluating the efficacy and safety of Saccharomyces boulardii CNCM I-745 in adult patients with non-constipated Irritable Bowel Syndrome.
Sponsor Biocodex
- Start (EU)
- Latest update
- Estimated end
- Not reported
ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases
Sponsor ARTIC
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study
Sponsor Gensight Biologics
- Start (EU)
- Latest update
- Estimated end
- Not reported
An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.
Sponsor Bioprojet Pharma
- Start (EU)
- Latest update
- Estimated end
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.7881 in adult patients with moderate-to-severe atopic dermatitis
Sponsor Bioprojet Pharma
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Exystat?
The 2026-10-09 snapshot links Exystat to 11 distinct CTIS trials. Recorded services include Statistical analysis, Data management, Electronic data capture, Interactive response technology (IRT), among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Exystat?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Haematological Malignancies, Dermatology. Recorded phases include Phase 3, Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Exystat conducted?
The linked trials record locations in 13 countries, including France, Belgium, Spain, Germany, Italy. These are trial locations, not confirmed office locations or countries where Exystat delivered services.
What can this page tell me about Exystat's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Exystat. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Exystat